Genmab Shares Jump 13% After Positive Late-Stage Cancer Trial Results
Genmab said an experimental drug reduced the risk of death and disease progression for ovarian-cancer patients in a late-stage trial. Shares rose 13% in European morning trade Monday.
By Adria CalatayudGenmab shares climbed after the Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.Shares in Genmab were up 13% in European morning trade Monday, lifting their year-to-date gain to nearl…